Timothy Warbington’s Post

The hidden dangers of prediabetes   Not only can the condition lead to diabetes, but it also increases your risk for cardio-vascular, kidney, and liver disease.   https://lnkd.in/ePRuM_bD   The article highlights the significant health risks associated with prediabetes and its progression to type 1 diabetes, a condition that remains challenging to manage. Advances in regenerative medicine, such as the CELZ-201 treatment being studied in the CREATE-1 clinical trial, aim to address the underlying causes of type 1 diabetes. By focusing on immunomodulation and improving immune regulation, this approach seeks to provide hope for patients impacted by the disease.    As research progresses, efforts by Creative Medical Technology Holdings Inc. (Nasdaq: CELZ) to improve patient outcomes and manage the complications associated with diabetes continue to grow in importance.    For more information on the CELZ-201 trial, visit https://lnkd.in/eZ8FAwYB #creativemedical #celz #nasdaq #biotech

FibroBiologics is exploring a new fibroblast-based approach to diabetes treatment, focusing on pancreatic beta cell spheroids for insulin secretion. This development could offer alternative management strategies for insulin-dependent diabetes. For a deeper understanding of this approach, hear from our Chief Scientific Officer, Dr. Hamid Khoja, about the implications for managing insulin-dependent diabetes. For more, please visit: https://bit.ly/3TmsS6j #DiabetesResearch #BiotechInnovation #Healthcare

Another FIRST brought to you by Truveta. This #GLP-1 #research explored GLP-1 #discontinuation + reinitiation #drugtrends and factors for #obesity and #weightloss. Over 96K patients were analyzed, suggesting that weight change, income, gastrointestinal #adverseevents, and #comorbidities play significant roles. Learn more about the findings and see which groups are more likely to re-start medication below! #rwe #rwd #treatmenteffectiveness

Here is a simulation of my own beating heart, developed by @ELEM Biotech. Why are we developing Virtual Human Twins, and in particular hearts? ❤️ As the @World Heart Federation highlights, cardiovascular disease (CVD) is the leading cause of death worldwide, claiming more than 20.5 million lives every year. Replicating the complex environment of CVD for drug testing presents a major challenge because of its heterogeneity - factors such as comorbidities, age, and gender all impact drug efficacy. Additionally, the progressive nature of CVDs makes it difficult to predict long-term outcomes based solely on short-term trial data. This is where ELEM’s #VirtualHearts play a crucial role. By testing drugs using our innovative technology, we enable pharmaceutical companies to design SMART trials that account for population variability and pave the way for more effective and personalised treatments. 🌍 Want to contribute to the fight against CVD? Help raise awareness about its impact and promote small lifestyle changes, like better diet, exercising, and stress management, that can improve heart health. #CardiovascularHealth #UseHeart #VirtualHumanTwins #SMARTtrials #UseVirtualHearts

Rapid exacerbation of heart failure, better known as acute decompensated heart failure, is associated, despite current medical treatments, with a high morbi-mortality. The incoherent patient and/or treatment stratification, due to the absence of reliable prognostic bio-markers reflecting not only the patient’s pathological status but also outcome, as well as the insufficient comprehension of the mechanisms triggering and/or maintaining decompensation, is involved in this incoherent patient/treatment stratification. The present project, using a recently developed a murine model mimicking acute decompensation of heart failure patients after dietary change with excessive salt ingestion, should reveal O-GlcNAcase inhibition as a new treatment for acute de compensation, the mechanisms involved and relevant biomarkers of acute decompensation, which will improve patient and treatment stratification, but might also reveal new targets for the treatment of decompensated heart failure. The GANDHI Project is led by Paul Mulder ( Mulder Paul ) , Université de Rouen Normandie  #CardInnov_E4H

Currently in clinical trials, senolytics are an exciting, potentially new class of therapies that target #senescent cells and could change the way we approach chronic and inflammatory diseases.     Our #senolytic agent is designed to target and clear senescent cells in diabetic retinas, allowing the damaged tissue to heal itself and potentially restoring vision for patients living with #DME. See our scientific approach and recent clinical data outlined in Nature’s article here: https://bit.ly/3QPwlcZ  

The American Diabetes Association returns for its 84th Annual Scientific Session on June 21st, bringing together researchers, healthcare professionals, and industry experts to delve into the latest advancements in diabetes research, treatment, and care.    With session themes focusing on therapeutics, management of acute or chronic complications, and behavioural medicine, it’s worth highlighting that the effectiveness of any treatment depends on its efficacy, safety, and patient adherence. Patient-centric integrated care approaches that enable real-time patient monitoring play a pivotal role in ensuring medication adherence and mitigating the risk and severity of complications associated with obesity, such as diabetes and hypertension.   Get in touch to arrange a meeting with Hakim Yadi Ph.D. OBE! Learn more about how Closed Loop Medicine is facilitating personalized disease management through our expanding portfolio of drug-plus-software combination products, to improve the effectiveness of medicines, such as GLP-1s, while reducing the impact of adverse effects:  https://shorturl.at/fMcea   #ADA2024 #TechBio #PrecisionCare

Looking forward to engaging with thought leaders across academia, industry and healthcare on the future of a more personalised, tolerable approach to GLP-1 therapy at the American Diabetes Association annual conference later this month. GLP-1s have brought a step change in outcomes for patients living with T2D and obesity but with 30% of patients stopping after 4 weeks before reaching target dose, we need a more personalised therapy regimen (https://lnkd.in/e_H--miH). At Closed Loop Medicine we are taking a precision medicine approach to disease management - including GLP-1. Treating the individual, not just the disease. #ADA2024 #TechBio #PrecisionCare #GLP1

The effectiveness of #thiamine in reducing #fatigue, especially in #IBD patients, may be related to specific #microbiota ! [Preprint] [Clinical Trial] [2024] NOTES: - #Butyrate and Butyrate-producing bacteria were similar in IBD patients with and without Fatigue and did not change with high-dose Thiamine treatment. - #Faecalibacterium_prausnitzii was more abundant in Thiamine responders compared with non-responders both pre-treatment and post-treatment. - The relative abundances of Faecalibacterium prausnitzii and #Roseburia_hominis, both pre- and post-treatment, inversely correlated with IBD Fatigue score changes for patients with chronic Fatigue. MyNotes: - May such relation also exist in other fatigue condition? (see my comments below) https://lnkd.in/eQkwghQC